Literature DB >> 16146847

Hepatosplenic αβ T-cell lymphoma with myelodysplastic syndrome.

Tomoiku Takaku1, Keisuke Miyazawa, Goro Sashida, Nahoko Shoji, Takashi Shimamoto, Noritake Yamaguchi, Yoshikazu Ito, Shigeo Nakamura, Kiyoshi Mukai, Kazuma Ohyashiki.   

Abstract

We describe a patient with hepatosplenic 33 T-cell lymphoma who showed pancytopenia and myelodysplasia. A 35-year-old man was admitted with fever, pancytopenia, and hepatosplenomegaly but with no lymphadenopathy. We also found trilineage myelodysplasia in the bone marrow on his first admission. The patient had high fever and anemia but no evidence of infection and was tentatively treated with prednisolone. This treatment resulted in a transient improvement of the cytopenia and a reduction of spleen size. However, 10 months after the first manifestation, progression of the splenomegaly and fever became apparent, and a splenectomy was performed. The pathologic findings for the spleen showed diffuse and disseminated infiltration of medium- to large-sized T-lymphocytes in the splenic red pulp. These cells were immunohistochemically positive for CD3, CD5, CD7, CD8, CD16, CD56,T-cell receptor 33 (TCR33),T-cell intracellular antigen 1, and granzyme B but were negative for CD4, CD30, CD57, and TCR33. These data suggested a diagnosis of hepatosplenic 33 T-cell lymphoma. A Southern blot analysis revealed gene rearrangement of the TCR 3-chain gene but not the immunoglobulin heavy chain gene in the spleen cells. An in situ hybridization analysis for the Epstein-Barr virus revealed negative results. The patient received 8 courses of combination chemotherapy and achieved a partial remission; however, the dysplastic features of the marrow cells persisted after the partial remission was obtained. Additional treatment with allogeneic bone marrow transplantation resulted in a transient complete remission; however, the patient relapsed 11 months later. Because he had experienced no lymphadenopathy and showed dysplastic features in the bone marrow, the diagnosis was highly dependent on the pathologic findings for the resected spleen.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16146847     DOI: 10.1532/IJH97.04149

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  15 in total

1.  Primary malignant lymphomas of the spleen. A morphologic and immunohistochemical analysis of 17 cases.

Authors:  S Falk; H J Stutte
Journal:  Cancer       Date:  1990-12-15       Impact factor: 6.860

2.  Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas.

Authors:  W R Macon; N B Levy; P J Kurtin; K E Salhany; M Y Elkhalifa; T T Casey; F E Craig; C L Vnencak-Jones; M L Gulley; J P Park; J B Cousar
Journal:  Am J Surg Pathol       Date:  2001-03       Impact factor: 6.394

3.  Hepatosplenic T-cell lymphoma of alphabeta lineage in a 16-year-old boy presenting with hemolytic anemia and thrombocytopenia.

Authors:  R Lai; L M Larratt; W Etches; S T Mortimer; L D Jewell; L Dabbagh; R W Coupland
Journal:  Am J Surg Pathol       Date:  2000-03       Impact factor: 6.394

4.  Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gamma/delta T-cell lymphomas.

Authors:  P Gaulard; P Bourquelot; P Kanavaros; C Haioun; J P Le Couedic; M Divine; M Goossens; E S Zafrani; J P Farcet; F Reyes
Journal:  Am J Pathol       Date:  1990-09       Impact factor: 4.307

5.  Anaplastic large-cell lymphoma which showed severe inflammatory status and myelodysplasia with increased VEGF and IL-6 serum levels after long-term immunosuppressive therapy.

Authors:  T Shimamoto; S Hayashi; K Ando; M Yguchi; K Miyazawa; Y Kimura; K Mukai; H Serizawa; K Ohyashiki
Journal:  Am J Hematol       Date:  2001-01       Impact factor: 10.047

6.  A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303.

Authors:  Y Yamada; M Tomonaga; H Fukuda; S Hanada; A Utsunomiya; M Tara; M Sano; S Ikeda; K Takatsuki; M Kozuru; K Araki; F Kawano; M Niimi; K Tobinai; T Hotta; M Shimoyama
Journal:  Br J Haematol       Date:  2001-05       Impact factor: 6.998

Review 7.  Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990.

Authors:  E Weidmann
Journal:  Leukemia       Date:  2000-06       Impact factor: 11.528

8.  Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin.

Authors:  C B Cooke; L Krenacs; M Stetler-Stevenson; T C Greiner; M Raffeld; D W Kingma; L Abruzzo; C Frantz; M Kaviani; E S Jaffe
Journal:  Blood       Date:  1996-12-01       Impact factor: 22.113

Review 9.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

Review 10.  Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients.

Authors:  Karim Belhadj; Felix Reyes; Jean-Pierre Farcet; Herve Tilly; Christian Bastard; Regis Angonin; Eric Deconinck; Frederic Charlotte; Veronique Leblond; Eric Labouyrie; Pierre Lederlin; Jean-Francois Emile; Beatrice Delmas-Marsalet; Bertrand Arnulf; Elie-Serge Zafrani; Philippe Gaulard
Journal:  Blood       Date:  2003-08-07       Impact factor: 22.113

View more
  4 in total

1.  Hepatosplenic αβ T-cell lymphoma associated with azathioprine therapy.

Authors:  Armin Rashidi; Michael E Lee; Stephen I Fisher
Journal:  Int J Hematol       Date:  2012-04-22       Impact factor: 2.490

2.  Hepatosplenic alphabeta T cell lymphoma.

Authors:  Yuya Nagai; Kazuhiro Ikegame; Minako Mori; Daichi Inoue; Takaharu Kimura; Sonoko Shimoji; Katsuhiro Togami; Sumie Tabata; Masayuki Kurata; Yukihiro Imai; Akiko Matsushita; Kenichi Nagai; Hiroyasu Ogawa; Takayuki Takahashi
Journal:  Int J Clin Oncol       Date:  2010-03-10       Impact factor: 3.402

3.  Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma.

Authors:  A Rashidi; A F Cashen
Journal:  Blood Cancer J       Date:  2015-06-05       Impact factor: 11.037

Review 4.  Bone Marrow Immunity and Myelodysplasia.

Authors:  Claude Lambert; Yuenv Wu; Carmen Aanei
Journal:  Front Oncol       Date:  2016-07-20       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.